Table 1 Baseline characteristics of the overall study population by working and non-working groups
From: Quality of life and work functionality in severe asthma patients: the impact of biological therapies
Study population N = 52 | Non-workers, N = 22 | Workers, N = 30 | P-value | |
|---|---|---|---|---|
Age (M ± DS) | 57 ± 11.7 | 61 ± 15 | 54 ± 9 | 0.057 |
Gender N (%) | 0.005 | |||
F | 26 (50%) | 16 (73%) | 10 (33%) | |
M | 26 (50%) | 6 (27%) | 20 (67%) | |
BMI (M ± SD) | 27.4 ± 3.4 | 28.4 ± 3.0 | 26.7 ± 3.7 | 0.071 |
Age at diagnosis (M ± SD) | 32.3 ± 12.6 | 33 ± 13 | 32 ± 13 | 0.778 |
Smoking status N (%) | 0.615 | |||
Non-smokers | 44 (84%) | 20 (91%) | 24 (80%) | |
Smokers | 3 (6%) | 1 (4.5%) | 2 (6.7%) | |
Ex-smokers | 5 (10%) | 1 (4.5%) | 4 (13%) | |
Education level N (%) | 0.028 | |||
A | 21 (40.4%) | 10 (45%) | 11 (37%) | |
B | 23 (44.2%) | 12 (55%) | 11 (37%) | |
C | 8 (15.4%) | 0 (0%) | 8 (27%) | |
Exacerbations in the preceding 12 months (M ± SD) | 2.90 ± 0.72 | 2.95 ± 0.79 | 2.87 ± 0.68 | 0.846 |
Atopy N (%) | 15 (29%) | 3 (14%) | 12 (40%) | 0.038 |
Nasal polyposis N (%) | 22 (42%) | 7 (32%) | 15 (50%) | 0.190 |
Drug N (%) | 0.821 | |||
Benralizumab | 17 (33%) | 7 (32%) | 10 (33%) | |
Dupilumab | 23 (44%) | 9 (41%) | 14 (47%) | |
Mepolizumab | 12 (23%) | 6 (27%) | 6 (20%) | |
ACT (M ± SD) | 11.6 ± 2.3 | 12.18 ± 1.92 | 11.20 ± 2.57 | 0.121 |
Spirometric values (M ± SD) | ||||
FEV1 L | 2.1 ± 0.6 | 1.93 ± 0.72 | 2.28 ± 0.52 | 0.057 |
FEV1% | 71.7 ± 12.8 | 72 ± 14 | 72 ± 12 | 0.929 |
FVC L | 3.4 ± 1.1 | 3.05 ± 1.15 | 3.72 ± 0.95 | 0.031 |
FVC % | 91.1 ± 11.9 | 90 ± 13 | 92 ± 11 | 0.511 |
FEV1/FVC | 63.1 ± 9.9 | 62 ± 11 | 64 ± 9 | 0.571 |
FeNO (M ± SD) (ppb) | 28.3 ± 5.3 | 26.7 ± 2.5 | 29.4 ± 6.5 | 0.044 |
Eosinophils (M ± SD) (n/μL) | 467.7 ± 213.1 | 483 ± 242 | 457 ± 193 | 0.677 |